Genfit Announces Financial Calendar for 2026
On January 7, the biopharmaceutical group Genfit released its financial calendar for the year 2026, according to a statement distributed to investors.
Provisional Financial Calendar for 2026
GENFIT (Euronext: GNFT), a biopharmaceutical company specializing in rare liver diseases, has unveiled its provisional financial calendar for the year 2026. According to the statement released on January 7, 2026 (source: GENFIT, Investor Relations), key upcoming dates include the publication of revenue and cash position as of December 31, 2025, on February 26, 2026, followed by the annual results of 2025 on April 2, 2026. The group also plans to post the Universal Registration Document 2025 and the annual financial report by the end of April 2026, followed by first quarter revenues on May 21, 2026, the General Meeting on June 15, 2026, the half-year accounts on September 29, 2026, and third quarter figures on November 5, 2026. GENFIT notes that this calendar may be subject to changes.
Importance of Publishing a Financial Calendar
The publication of a financial calendar is a requirement for companies listed on regulated European markets. This document allows both institutional and individual investors to plan their analysis and investment decisions based on the dates of financial results communication. For Genfit, listed on both Euronext Paris and the Nasdaq in the United States, this communication meets the requirements of both jurisdictions. The group must comply with the transparency obligations imposed by the French Financial Markets Authority and the U.S. Securities and Exchange Commission. The release of the calendar at the beginning of the year also allows analysts to structure their financial coverage of the company.
About Genfit
Genfit is a biopharmaceutical company focused on the development of treatments and diagnostic solutions for liver diseases. The company, headquartered in Lille, France, also has facilities in Cambridge, Massachusetts, USA, and Zurich, Switzerland. The company's shares are traded on Euronext Paris's Compartment B under the ticker symbol GNFT, as well as on the Nasdaq Global Select Market. The company focuses its research and development efforts on metabolic and inflammatory pathologies affecting the liver. The group joined the Nasdaq in 2019, thereby expanding its investor base to the American market.
